USD 0.38
(-3.43%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 109 Thousand USD | -70.54% |
2022 | 370 Thousand USD | -75.33% |
2021 | 1.5 Million USD | 0.0% |
2020 | - USD | -100.0% |
2019 | 2.19 Million USD | -28.96% |
2018 | 3.09 Million USD | -32.85% |
2017 | 4.6 Million USD | 8.82% |
2016 | 4.23 Million USD | 185.23% |
2015 | 1.48 Million USD | 159.72% |
2014 | 571 Thousand USD | 50.66% |
2013 | 379 Thousand USD | -68.34% |
2012 | 1.19 Million USD | 0.0% |
2010 | - USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 39 Thousand USD | 34.48% |
2023 Q3 | 5000.00 USD | 0.0% |
2023 Q1 | 75 Thousand USD | -53.7% |
2023 Q2 | - USD | -100.0% |
2023 FY | 109 Thousand USD | -70.54% |
2023 Q4 | 29 Thousand USD | 480.0% |
2022 FY | 370 Thousand USD | -75.33% |
2022 Q4 | 162 Thousand USD | 23.66% |
2022 Q3 | 131 Thousand USD | 70.13% |
2022 Q2 | 77 Thousand USD | 0.0% |
2022 Q1 | - USD | -100.0% |
2021 Q1 | - USD | 100.0% |
2021 Q2 | - USD | 0.0% |
2021 FY | 1.5 Million USD | 0.0% |
2021 Q4 | 1.5 Million USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2020 Q1 | - USD | -100.0% |
2020 Q4 | -0.01 USD | -626.89% |
2020 Q2 | 0.01 USD | 0.0% |
2020 FY | - USD | -100.0% |
2020 Q3 | - USD | -76.57% |
2019 Q2 | 1.23 Million USD | 84.13% |
2019 FY | 2.19 Million USD | -28.96% |
2019 Q4 | 258 Thousand USD | -13.42% |
2019 Q3 | 298 Thousand USD | -75.77% |
2019 Q1 | 668 Thousand USD | -1.76% |
2018 Q1 | 689 Thousand USD | -37.65% |
2018 FY | 3.09 Million USD | -32.85% |
2018 Q4 | 680 Thousand USD | -12.71% |
2018 Q3 | 779 Thousand USD | -17.39% |
2018 Q2 | 943 Thousand USD | 36.87% |
2017 Q2 | 1.35 Million USD | 36.87% |
2017 Q1 | 990 Thousand USD | 21.92% |
2017 Q4 | 1.1 Million USD | -4.16% |
2017 FY | 4.6 Million USD | 8.82% |
2017 Q3 | 1.15 Million USD | -14.91% |
2016 Q2 | 1.37 Million USD | 54.43% |
2016 Q4 | 812 Thousand USD | -29.45% |
2016 FY | 4.23 Million USD | 185.23% |
2016 Q1 | 891 Thousand USD | 62.59% |
2016 Q3 | 1.15 Million USD | -16.35% |
2015 FY | 1.48 Million USD | 159.72% |
2015 Q4 | 548 Thousand USD | 67.07% |
2015 Q3 | 328 Thousand USD | 8.97% |
2015 Q2 | 301 Thousand USD | -1.63% |
2015 Q1 | 306 Thousand USD | 14.61% |
2014 Q1 | 99 Thousand USD | -13.91% |
2014 FY | 571 Thousand USD | 50.66% |
2014 Q4 | 267 Thousand USD | 72.26% |
2014 Q3 | 155 Thousand USD | 210.0% |
2014 Q2 | 50 Thousand USD | -49.49% |
2013 FY | 379 Thousand USD | -68.34% |
2013 Q2 | 23 Thousand USD | -78.3% |
2013 Q1 | 106 Thousand USD | -50.7% |
2013 Q4 | 115 Thousand USD | -14.81% |
2013 Q3 | 135 Thousand USD | 486.96% |
2012 Q1 | 258.97 Thousand USD | 115.81% |
2012 Q2 | 469.23 Thousand USD | 81.19% |
2012 Q3 | 348.78 Thousand USD | -25.67% |
2012 Q4 | 215 Thousand USD | -38.36% |
2012 FY | 1.19 Million USD | 0.0% |
2011 Q2 | 1677.00 USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2011 Q3 | - USD | -100.0% |
2011 Q4 | 120 Thousand USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Xeris Biopharma Holdings, Inc. | 163.91 Million USD | 99.934% |
Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 99.955% |
Codexis, Inc. | 70.14 Million USD | 99.845% |
Viridian Therapeutics, Inc. | 314 Thousand USD | 65.287% |